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Background: The group of small blue round cell tumors encompasses a heterogeneous group of neoplasms
characterized by primitive appearing round cells with few distinguishing histologic features.
Results: We report the case of a small blue round cell tumor with an EWS gene rearrangement detected by
fluorescent in situ hybridization (FISH) analysis that mimicked Ewing sarcoma, but with unusual histology and
immunohistochemical features. Multi-color karyotyping identified the presence of a t(2;22)(q34;q12) that was
initially expected to represent a variant EWSR1-FEV translocation. After an extensive workup, the lesion is
considered to represent a clear cell sarcoma harboring an EWSR1-CREB1 fusion transcript.
Conclusions: This case appears to represent a rare variant of clear cell sarcoma arising in peripheral soft tissues
with unusual histology and unique immunophenotype. In this circumstance, FISH for all EWSR1 translocation
partners or RT- PCR for a spectrum of possible transcript variants is critically important for diagnosis, since
cytogenetic analysis or clinical FISH assay using only commercial EWSR1 probes will be misleading.
Background
The accurate diagnosis of small blue round cell neo-
plasms can be difficult. The differential diagnosis
includes sarcomas (such as the Ewing family of tumors
(EFT), alveolar rhabdomyosarcoma, poorly differentiated
synovial sarcoma, myxoid/round cell liposarcoma, des-
moplastic small round cell tumor, and cellular variants
of extraskeletal myxoid chondrosarcoma), small cell and
lymphoblastic lymphomas, neuroblastoma, melanoma
and small cell carcinoma among others.
Although certain histologic features may be useful in
differentiating these entities, their general morphology is
generic by light microscopy and a large battery of ancil-
lary studies is required. Immunohistochemistry is the
first line supplemental methodology and is sufficient for
diagnosis in many cases of small round cell tumors. For
example, myogenin and myoD1 are specific and sensi-
tive for the diagnosis of rhabdomyosarcoma [1] and
lymphoid markers such as CD20, CD3, CD30 and CD45
are very useful in the diagnosis of lymphoma. However,
many other markers, although helpful, are not so speci-
fic and require interpretation in the context of an
immunohistochemical panel. For example, epithelial
markers are essential for the diagnosis of carcinoma, but
they can also be positive in poorly differentiated synovial
sarcoma, Merkel cell carcinoma and in rare Ewing
family tumors [2]. S-100 is positive in melanoma but
also in clear cell sarcoma, myxoid liposarcoma, extra-
skeletal myxoid chondrosarcoma and some Ewing family
tumors; desmin is strongly positive in rhadomyosarcoma
but is also positive in desmoplastic small round cell
tumor; and CD99 immunoreactivity is seen in EFT, but
also in mesenchymal chondrosarcoma and lymphoblastic
lymphoma [3].
FISH analyses for chromosomal translocations can be
extremely helpful in this setting, but even these findings
may not be specific. EWSR1 gene rearrangement is char-
acteristic of EFT, but is also present in extraskeletal
myxoid chondrosarcoma, desmoplastic small round cell
tumor, and a subset of myxoid/round cell liposarcomas
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Karyotype analysis is a global genome scan that has
the ability to detect gross chromosomal alterations such
as translocations, but the precise chromosomal bands
and breakpoints involved in the identified translocations
may be inaccurate due to the very low resolution of this
technique.
Here we report on a small blue round cell tumor with
an unusual combination of histological and immuno-
histochemical findings. Results from standard first line
molecular cytogenetic studies turned out to be mislead-
ing for both diagnosis and therapy. A complete workup
including karyotype analysis, multicolor FISH and con-
struction of new FISH probes was required for the defini-
tive diagnosis of what we consider to represent a variant
of clear cell sarcoma bearing an EWSR1-CREB1 fusion
transcript and expressing an aberrant immunophenotype.
Case presentation
Clinical details
54-year-old female presented with pain and swelling of
one year duration in her left leg. An MRI scan revealed
a 7 cm enhancing mass lying in the posterior calf, at the
level of popliteus muscle and extending through the
interosseous membrane. The tibial nerve and popliteal
vessels were encased in the tumor. Systemic imaging
revealed no metastases.
A core needle biopsy was taken, but proved insuffi-
cient for a definitive diagnosis. An open biopsy was per-
formed and a working diagnosis of soft tissue Ewing
sarcoma rendered. The patient received pre-operative
systemic chemotherapy as for Ewing sarcoma, but failed
to respond with any tumor shrinkage.
For local treatment of her tumor she was advised to
undergo above knee amputation due to the anticipated
poor functional results of limb salvage in this situation.
Despite extensive counseling and corroborating second
opinions she refused amputation. As limb salvage was
technically feasible, she underwent pre-operative radiation
therapy and a complex wide resection of the tumor was
performed, with tibial nerve resection, vascular reconstruc-
tion with saphenous vein grafts, allograft reconstruction
and internal fixation of the tibial defect, as well as recon-
struction of the soft tissue defect with a free tissue transfer
from the scapular region. Wide margins were achieved.
The patient developed a wound infection with methicillin-
resistant S. aureus 14 days postoperatively. At day 22, she
suffered an anastomotic leak of the vessel reconstruction.
Although vascularity was restored and her limb at this
stage was still viable, she was very disappointed with the
functional results of her procedure and requested an above
knee amputation. She was clear of disease at last follow up.
Results
Core needle biopsy
Sections showed a small blue round cell tumor growing
in poorly cohesive sheets. The tumor cells had uniform
plasmacytoid cytology (Fig. 1). A morphologically sus-
pected diagnosis of plasma cell myeloma was ruled out
based on the lack of immunoreactivity for kappa or
lambda light chains. Instead, the tumor cells showed
striking CD99, synapthophysin and desmin immunor-
eactivity. In contrast, other immunohistochemical mar-
kers were all negative, including melanocytic markers
such as S-100, HMB-45 and Melan-A. The results of
immunohistochemistry are shown in Table 1 with some
relevant immunohistochemical staining patterns illu-
strated in Figure 1.
The main differential diagnoses were considered to be
Ewing family tumor and alveolar rhabdomyosarcoma.
Alveolar rhabdomyosarcoma was ruled out by negative
myogenin and myoD1 and by absence of PAX3/PAX7-
FKHR translocations by FISH. EWSR1 FISH, in contrast,
showed a break-apart signal pattern in most of the
interphase nuclei. A provisional diagnosis of Ewing sar-
coma was rendered. However, the histology, the absence
of Fli1 staining and the strong desmin immunoreactivity
were all considered unusual by several local and consul-
tant pathologists who reviewed the case.
Additional FISH assays for WT1, CHN and DDIT3 (3′
partners of EWSR1 in desmoplastic round cell tumor,
extraskeletal myxoid chondrosarcoma and round cell
liposarcoma, respectively) were negative. All core needle
biopsy tissue had been consumed after these assays.
In view of the major therapeutic implications engen-
dered by a diagnosis of Ewing sarcoma, a decision was
made to perform an open biopsy to obtain more tissue
including fresh tissue for cytogenetics.
Open biopsy
An open biopsy was performed 6 weeks after the origi-
nal core needle procedure. Histological examination of
this specimen revealed plasmacytoid cells with small,
eccentric, uniform, moderately vesicular nuclei, most
with a single central nucleolus. The tumor cells were
arranged in poorly cohesive sheets with no associated
necrosis and occasional mitotic figures were evident.
Results of immunohistochemical studies were similar to
those found on the core biopsy. Other immunohisto-
chemical markers were ordered and found to be nega-
tive, including EMA, CD68, PNL2 and WT1.
The cultured tumor specimen did not yield metaphases
of sufficient quality to be analyzed by G-banding. Multi-
color karyotyping identified a few metaphases that con-
tained a reciprocal translocation between 2 q and 22 q in
the context of additional numerical and structural
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lished as 46, XX, t(2;22)(q?36;q?12), +5, t(14;21)(q?;q?),
-21 [5] (Fig. 2). On this basis the diagnosis of Ewing sar-
coma was considered confirmed as these findings were
consistent with the variant t(2;22) EWS-FEV fusion. At
this point neoadjuvant chemotherapy was initiated for
Ewing sarcoma.
Characterization of the translocation t(2;22)
To confirm the suspected EWS-FEV translocation, a
dual-color break-apart probe for FEV on chromosome
band 2q36 [6] was applied to the cultured specimen. The
scoring with this probe revealed two intact signals in the
interphase nuclei, with one metaphase showing an intact
copy of FEV abnormally located on der(22)t(2;22). FISH
for EWSR1 was performed on the same slide and showed
rearrangement in most of the interphase nuclei with the
3′ probe signal located on der(2)t(2;22) (Fig. 2b). These
findings indicated that FEV was not rearranged as
expected, and that the breakpoint on the der(2)t(2;22)
was in fact centromeric to the FEV locus.
A candidate gene approach was initiated to establish
the variant EWSR1 fusion partner. CREB1 is the only
other gene in this region previously identified in sar-
coma translocations, and a break-apart CREB1 probe
was created and applied to the cultured specimen. With
this FISH experiment, break-apart signals in ~80% of
the interphase nuclei were observed (Fig. 2c). The reci-
procal t(2;22)(q34;q12) was confirmed using a EWSR1-
CREB1 dual-fusion probe that revealed the expected
fusion signals.
Agarose gel electrophoresis of the RT-PCR product
showed a ~120 bp band (Fig. 3a). The size of the pro-
duct corresponded to the predicted product size of the
fragment spanning the fusion transcript breakpoint
based on the primer design from published cDNA
sequences for EWSR1 (NM_013986.2) and CREB1
(NM_004379.3). Cloning and sequencing of this product
showed an in-frame fusion between EWSR1 exon 7 and
CREB1 exon 7 (Fig. 3b).
Following this workup and considering also the lack of
response to neoadjuvant therapy, a diagnosis of clear
Figure 1 Microscopic appearance and immunohistochemical features of the tumor. A) Representative area of the core needle biopsy
specimen showing a homogeneous plasmacytoid appearance of the tumor cells (H&E; ×100 magnification). B) Desmin and C) CD99 strong
immunoreactivity (×200 magnification). D) S100 and E) HMB-45 immunohistochemical staining (×200 magnification). F) Representative area of
the resection specimen showing nests of tumor cells with clear cytoplasm divided by thin fibrous septa (×100 magnification).
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nophenotype was considered.
Surgical specimen
The resection specimen revealed a high-grade sarcoma
with areas similar to those found in the biopsies, but
also other areas with neoplastic cells with clear cyto-
plasm arranged in a nested pattern (Fig. 1f). Extensive
infiltration of malignant cells through soft tissues and
the dense fascia of the periosteum and interosseous
membrane was evident as was extensive lymphovascular
invasion. Immunohistochemistry was repeated and while
HMB45 remained negative and CD99 strongly positive,
S-100 and Melan-A now revealed patchy positive stain-
ing. These new findings led us to favor a final diagnosis
of clear cell sarcoma.
Discussion
Clear cell sarcoma (CCS) is an aggressive neoplasm of
uncertain histogenesis, accounting for 1% of soft tissue
sarcomas. The deep soft tissues of the distal extremities
are most frequently involved, often in association with
tendons and aponeuroses [7]. Unlike most sarcomas,
CCS has a high propensity for lymph nodes metastasis.
The tumor cells show immunoreactivity for melanocy-
tic markers [8,9] as they contain melanosomes in differ-
ent stages of development [10], and display melanocytic
gene expression signatures [11]. Despite its similarity
with melanoma, CCS is a distinct entity genetically char-
acterized by the presence of a chromosomal transloca-
tion involving EWSR1 most frequently partnered with
ATF1 [10,12-14]. More recently, the alternative chimeric
transcript EWSR1-CREB1 has been described in three
cases of clear cell sarcoma of the gastrointestinal tract
that, interestingly, did not show overt melanocytic dif-
ferentiation [15]. The same chimeric transcript, resulting
from a presumed t(2;22)(q34;q12) has been described in
three cases of CCS of soft tissue to date [13,14]. Hisaoka
et al [13] found this chimeric transcript in 2 of 33 cases
of CCS (6%). One presented as a 1.5 cm mass in the fin-
ger of a 67-year-old male, and the other as a 15 cm
mass in the pelvis of a 31-year-old female. Wang et al
Table 1 Methods and results of immunohistochemistry
Antibody Source Dilution/antigen retrieval Detection method Reactivity
CK AE1/AE3 Dako 1:200/protease digestion SA/Bi -
CK7 Dako 1:200/protease digestion SA/Bi -
CK20 Dako 1:500/protease digestion SA/Bi -
TTF1 Dako 1:100/CC1/95°C/30 min SA/Bi -
EMA Dako 1:200/CC1/95°C/30 min SA/Bi -
Vimentin Biogenex 1:10000/CC1/95°C/30 min SA/Bi -
CD20 Dako 1:250/CC1/95°C/30 min SA/Bi -
CD30 Dako 1:50/CC1/95°C/30 min SA/Bi -
CD34 Cell Marque 1:50/CC1/95°C/30 min SA/Bi -
Kappa light chain Dako 1:5000/protease digestion SA/Bi -
Lambda light chain Dako 1:10000/protease digestion SA/Bi -
CD68 Dako 1:800/CC1/95°C/8 min SA/Bi -
S-100 Univ. of Toronto 1:1000/CC1/95°C/30 min SA/Bi - *
HMB-45 Dako 1:100/untreated SA/Bi -
Melan-A Cell Marque 1:50/CC1/95°C/30 min SA/Bi - *
PNL2 Private source RTU/untreated Polymer based -
SMA Dako 1:200/untreated SA/Bi -
Desmin Dako 1:200/CC1/95°C/30 min SA/Bi +++
H-Caldesmon Dako 1:200/CC1/95°C/30 min SA/Bi -
Myogenin Dako 1:50/CC1/95°C/60 min Polymer based -
Myo-D1 Dako 1:60/citrate buffer (pH6.0) Polymer based -
CD99 Signet 1:20/CC1/95°C/30 min SA/Bi +++
Synaptophysin Cell Marque 1:250/CC1/95°C/30 min SA/Bi +++
Fli1 BD Pharmingen 1:20/CC1/95°C/60 min Polymer based -
WT1 Dako 1:50/CC1/95°C/60 min Polymer based -
Ki 67 Lab Vision 1:200/CC1/95°C/30 min SA/Bi >10%
Dako, Carpinteria, CA, USA; Biogenex, San Ramon, CA, USA; Cell Marque, Rocklin, CA, USA; Signet, Dedham, MA, USA; BD Pharmingen, Franklin Lakes, NJ, USA.
SA/Bi: Streptavidin/biotin method; RTU: ready to use; CC1: Cell conditioning 1 (pH8.0) (Ventana medical systems, Tucson, AZ, USA).
*Negative on the core and open biopsies, but patchy positive staining was identified in the resection specimen.
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2, normal chromosome 22 and both derivative chromosomes resulting from t(2;22)(q?36;q?12). B) Metaphase FISH with EWSR1 break-apart probe.
An intact dual-color EWSR1 signal can be seen on normal chromosome 22, a green signal on the der(2) and a red signal on the der(22). C)
Interphase FISH with the CREB1 break-apart probe showing break-apart signals (1 fused, 1 green and 1 red signals).
Figure 3 Agarose gel of EWSR1-CREB1 RT-PCR product and sequence of the junction point. A) RT-PCR product of ~120 bp corresponding
to the predicted size of the fragment spanning the break point based on the pair of primers used. M, 100 bp molecular marker; NC, negative
control (molecularly confirmed clear cell sarcoma with an EWSR1-ATF1 translocation); NTC, no template control. B) Sequence electropherogram
showing an EWSR1 exon7/CREB1 exon 7 in-frame fusion.
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of 15 cases (~7%), a superficial tumor in the palm of a
66-year-old female.
EWSR1-ATF1 and EWSR1-CREB1 are not exclusively
found in CCS. They also are the most common gene
fusions in angiomatoid fibrous histiocytoma, a mesench-
ymal neoplasm of borderline malignancy of children and
young adults [16,17] that typically presents as a small
superficial mass with a distinctive histology (nodules of
histiocytoid cells, pseudoangiomatoid blood-filled spaces,
fibrous pseudocapsule with a pericapsular lymphoplas-
macytic infiltrate). None of these typical clinical features
nor morphologic hallmarks were present in the current
tumor.
Typically, CCS is composed of nests of plump spindle
cells with clear to pale eosinophilic cytoplasm, separated
by delicate fibrous septa. The histology of the present
tumor was misleading as it presented as a monotonous
small round cell neoplasm, with most cells exhibiting
plasmacytoid characteristics. Deviation from the usual
histology has been seen in some cases of CCS
[10,13,18]. Areas with rhabdoid tumor cells were
detected in 24% and 16% of the molecularly confirmed
cases reported by Antonescu et al [10] and Hisaoka
et al [13]. However, to the best of our knowledge, des-
min expression by CCS cells has not been described
previously [13,19] and CD99 immunoreactivity has been
found only in one molecularly confirmed case of CCS of
the stomach [20]. Nevertheless, these are markers that
are not consistently tested in the clinical workup for
clear cell sarcoma, as small blue round cell tumors such
as Ewing sarcoma and rhabdomyosarcoma are not part
of the usual histological differential diagnosis of CCS.
CCS of soft tissue is typically characterized by the
expression of S-100 and melanosome-associated markers
[10,13,14,18,21]. In this regard too, the present tumor
had a unique immunoprofile, as S-100, HMB45 and
M e l a n - Aw e r ea l ln e g a t i v ei nb o t ht h ec o r en e e d l ea n d
incisional biopsies. It was only in the resection specimen
that some patchy staining for S-100 and Melan-A was
seen. Lack of vimentin expression was also an unex-
pected finding.
In a setting of supportive histomorphology and
immunohistochemistry, detection of EWSR1 rearrange-
ments by FISH is a very useful diagnostic tool that can
support the diagnosis for the known set of EWSR1-
translocation bearing tumors (Ewing family tumors,
clear cell sarcoma, extraskeletal myxoid chondrosar-
coma, desmoplastic round cell tumor, and variant myx-
oid/round cell liposarcomas) [4]. Nevertheless, in light
of the lack of specificity of EWSR1 break apart probes in
the differential diagnosis of small round cell sarcomas,
t h es e a r c hf o ra3 ′ partner is very important in the
follow-up analysis when the histology is not entirely
classic for one of these diagnoses. The combined gen-
ome wide-screen provided by multicolor FISH, and the
advantage of metaphase FISH to detect rearrangements
with reference to specific chromosomal bands allowed
us to interrogate the involvement of CREB1 on chromo-
some band 2q34 as the EWSR1 3′ partner in the reci-
procal t(2;22).
The rate of detection of diagnostic chimeric tran-
scripts in CCS by RT-PCR ranges between 91%-100%
among published studies [10,12-14,18]. This minor dif-
ference could be explained by the fact that not all the
studies were intended to cover all the transcript variants,
and the negative cases may well represent tumors with
overlooked alternative chimeric transcripts. Interestingly,
the rate of detection of EWSR1 rearrangement in CCS
by FISH has been variously reported to be 70%, 88% or
100% [18,22,23], raising the possibility of EWSR1 being
substituted by other genes as a 5′partner in a small sub-
set of CCS.
Our case would represent the fourth soft tissue CCS
reported harboring this fusion transcript variant, and
the first in which the cytogenetic features of this reci-
procal translocation t(2;22)(q34;q12) are detailed. The
predicted structure of EWSR1-CREB1 in this case is
similar to that described previously [14-16] in which
the oncogenic chimeric transcript retains its CREB1
carboxyl-terminal basic leucine zipper DNA binding
and dimerization domain, fused to the amino-terminal
transcriptional activation domain of EWS which
confers oncogenic properties by transcriptional
dysregulation.
Conclusions
This case supports the fact that EWSR1-CREB1 is not a
translocation variant exclusive to clear cell sarcomas
arising in the gastrointestinal tract.
The described variation in histology and immunohis-
tochemical features displayed by CCS must be taken
into account when considering the differential diagnosis
for an unusual small blue round cell tumor. In this set-
ting, immunohistochemistry and even karyotype can be
misleading, and FISH for both of the translocation part-
ners or PCR primers accounting for all of the fusion
transcript variants is important for accurate diagnosis.
Methods
Tissue handling
T h ec o r en e e d l eb i o p s yw a sf i x e di nn e u t r a l - b u f f e r e d
formalin and processed for routine histology. Unstained
6 μm paraffin sections were submitted for interphase
FISH. Representative tissue from the incisional biopsy
and from the excision specimen were submitted
fresh for cytogenetic analysis and a portion was snap
frozen for molecular studies. The remaining tissue
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immunohistochemistry.
Immunohistochemistry
Standard immunohistochemical studies were done using
a Ventana Benchmark XT Instrument (Ventana medical
systems, Tucson, AZ, USA). The source and dilution of
the antibodies, antigen retrieval and the detection meth-
ods are presented in Table 1.
Cytogenetic studies, FISH and multicolor FISH
Chromosome analysis was performed by standard meth-
ods after 6 days culture in RPMI 1640 medium supple-
mented with 20% fetal calf serum and L-glutamine.
Metaphase chromosomes were banded by the GTG
method and the karyotypes were described according to
the International System for Human Cytogenetic
Nomenclature 2005 [24].
FISH was performed on sections from the core needle
biopsy and on cell preparations from the cultured inci-
sional biopsy specimen. Commercial probes for EWSR1,
FUS and DDIT3 (Abbott Molecular, Des Plaines, IL,
USA) and “in-house” dual-color break-apart (CHN,
WT1, FEV) and dual-color dual-fusion (PAX3-FKHR
and PAX7-FKHR) bacterial artificial chromosome (BAC)
probes were used. An “in house” dual-color break-apart
probe was prepared for the detection of CREB1 rearran-
gements using BACs RP11-354H1 and RP11-135B21.
An “in-house” dual-color, dual-fusion EWSR1-CREB1
probe was prepared to confirm the reciprocal t(2;22)
(q34;q12) using BACs RP11-135B21/RP11-354H1 (chro-
mosome 2) and RP11-945M21/RP11-1126O13 (chromo-
some 22).
The BAC probes were directly labeled by nick transla-
tion using either Spectrum Green or Spectrum Orange
(Abbott Laboratories, Abbott Park, IL, USA). The chro-
mosomal locations of the BACs were initially confirmed
by hybridization to normal metaphases from a periph-
eral blood culture. Each probe was scored by counting
200 interphase nuclei under fluorescent microscopy. For
confirmation of true breakapart, >10% of cells showing a
clear pattern of one fused, one red and one green signal
was required. For confirmation of dual fusions, >5% of
nuclei with a clear two fused, one red, one green pattern
was required.
Multicolor FISH was performed using the 24 XCyte
color kit (Metasystems, Altlussheim, Germany) following
the manufacturer’s protocol.
Reverse transcription-PCR of the fusion transcript
Total RNA from the frozen open biopsy tumor tissue
was isolated using the RNeasy mini kit (Qiagen, Mary-
land, USA). Two micrograms of total RNA were reverse
transcribed using the qScript cDNA SuperMix system
(Quanta Biosciences, Maryland, USA) and used as tem-
plate for PCR amplification of the EWS-CREB1 fusion
breakpoints using the following primers [14] EWSex7-
F1 primer (5′-TCCTACAGCCAAGCTCCAAGTC -3′)
and CREB1ex7-REVC primer specific for CREB1 (5′-
GTACCCCATCGGTACCATTGT -3′). The PCR ampli-
fication started with 5 minutes at 95°C; followed by 35
cycles of 30 seconds at 95°C, 30 seconds at 58°C, and 45
seconds at 72°C; and a final extension of 10 minutes at
72°C. PCR product was detected by 1.5% agarose gel
electrophoresis.
cDNA cloning and sequencing analysis of the fusion
transcript
The cDNA of the break-point-crossing fragment of the
EWS-CREB1 chimeric transcript was first amplified with
HindIII-EWSex7-FW (5′TATCaagcttTCCTACAGC-
CAAGCTCCAAGTC) and XhoI-CREB1ex7-RV (5′-
TTTTctcgagGTACCCCATCGGTACCATTGT), then
subcloned into pcDNA3.1 (+) vector. Purified plasmid
DNA was verified using the same restriction enzymes.
T h ec l o n e sw i t ha ni n s e r to ft h ea p p r o p r i a t es i z ew e r e
then submitted for cDNA sequencing using a T7-FW
primer.
Consent
Written informed consent was obtained from the patient
for publication of this case report. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
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